HUADONG MEDICINE(SZ:000963)2022-12-08 09:22Financial Performance - The company's overall production and operation met expected targets for Q3 2014 [1] - Core pharmaceutical subsidiary, Zhejiang Zhongmei Huadong Pharmaceutical Co., achieved over 30% revenue and net profit growth in the first three quarters of 2014 [2] - Pharmaceutical commercial revenue growth was approximately 12%, with net profit growth around 14% [2] Taxation and Profitability - Due to pending approval for high-tech enterprise qualification, a tax rate of 25% was provisioned [1] - If a 15% tax rate were applied, revenue and net profit growth would exceed 30% [2] Product Performance - Sales of Bailin capsules increased by over 30% in the first three quarters [2] - Akabose sales grew by approximately 40%, benefiting from inclusion in the national essential drug list [3] - Immunosuppressive products, except for Tacrolimus, showed steady growth [3] Strategic Developments - The company is actively preparing for Zhejiang province's essential drug bidding [2] - The company is exploring new partnerships in medical beauty, health products, and medical devices [4] - Jiangdong base is expected to resolve production capacity issues by 2016 [3] Funding and Expansion Plans - The company plans to distribute cash dividends of 0.7 RMB per share based on a total share capital of 434,059,991 shares [5] - A bond issuance of up to 1 billion RMB is under review by the China Securities Regulatory Commission [5] - The company is seeking acquisition opportunities in both pharmaceutical commerce and industry [5]